Andrew Bellinger

Chief Scientific Officer, Verve Therapeutics

Dr. Andrew Bellinger is the chief scientific and medical officer of Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Dr. Bellinger is a cardiologist and scientist who specializes in company creation and growth, building high-performing R&D teams, translational medicine, drug delivery, and has a particular interest in the clinical development of novel classes of therapies. He is a cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine. Verve is advancing two initial programs that target PCSK9 and ANGPTL3, respectively – genes that have been extensively validated as targets for lowering blood lipids, such as low-density lipoprotein cholesterol, which is a major driver of cardiovascular disease.

Prior to joining Verve, Dr. Bellinger co-founded and served as chief scientific officer of Lyndra Therapeutics, and prior to that as the chief scientific officer of Cocoon Biotech. He is also a co-founder of Corner Therapeutics.  Dr. Bellinger completed his clinical training in internal medicine at the University of California, San Francisco, and his clinical training in cardiology at Brigham and Women’s Hospital. He completed his postdoctoral research training in drug delivery with Dr. Robert Langer at the Massachusetts Institute of Technology. Dr. Bellinger holds an M.D., a Ph.D., and an MPhil from Columbia University, an M.S. in mathematics from New York University, and an A.B. in physics from Princeton University.